Pfizer’s reply to de Monteverde-RobbBMJ 2011; 343 doi: http://dx.doi.org/10.1136/bmj.d5962 (Published 21 September 2011) Cite this as: BMJ 2011;343:d5962
- Berkeley Phillips, medical director1
- 1Pfizer, Tadworth, Surrey KT20 7NS, UK
For several months Pfizer has faced supply issues with its intravenous preparation of lorazepam (Ativan), which until recently has been produced by a third party manufacturer, Recipharm, on behalf of Pfizer.1 On 30 June 2011, Recipharm informed Pfizer of the immediate closure of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial